Last reviewed · How we verify
NCT02907996
Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea
trial testing Sofosbuvir in Hepatitis C Virus in 2,033 participants. Completed in 9 December 2021.
9 December 2021
Quick facts
| Lead sponsor | Gilead Sciences |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,033 |
| Start date | 9 September 2016 |
| Primary completion | 9 December 2021 |
| Estimated completion | 9 December 2021 |
| Sites | 72 locations across South Korea |
Drugs / interventions tested
- Sofosbuvir — full drug profile →
Conditions studied
- Hepatitis C Virus — all drugs for Hepatitis C Virus →
Sponsor
Gilead Sciences — full company profile →
Who can join
12 and older, any sex, with Hepatitis C Virus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objectives of this study are to collect and assess data related to safety and effectiveness of Sovaldi treatment regimens, per the approved prescribing information for Sovaldi, in routine clinical practice and report results to Korean Ministry of Food and Drug Safety (MFDS).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02907996
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sofosbuvir
Trials testing the same drug.
- NCT05717400 — Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Inf · Phase 4 · terminated
- NCT04497649 — Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients · Phase 2, PHASE3 · unknown
- NCT04246723 — Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chr · Phase 2 · completed
- NCT04111367 — Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients · Phase 2 · unknown
- NCT03883698 — Safety of Sofosbuvir in People With Advanced Kidney Failure · Phase 3 · completed
Other Gilead Sciences trials
Trials by the same sponsor.
- NCT07115368 — Study of GS-1219 in Participants With HIV-1 · Phase 1 · terminated
- NCT06784973 — Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection · Phase 2 · terminated
- NCT06683482 — A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in Spain · completed
- NCT06613685 — Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated · Phase 2, PHASE3 · terminated
- NCT06585150 — Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02907996 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gilead Sciences
- Last refreshed: 27 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02907996.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing